Lupin Limited · NSE:LUPIN
Lupin — Q2 FY2020 Earnings Presentation
15 slides from Lupin's earnings presentation, Nov 6, 2019
Slide 1: Cover letter to BSE and NSE
November 6, 2019 The BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. ~e National Stock Exchange of India limited Exchange Plaza, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 . Dear Sirs, Sub:Q2 FY2020 Investor Presentation. Pursuant to Regulation 3
Slide 2: Investor Presentation Q2 FY2020
Investor Presentation Q2 FY2020 Nov 06, 2019
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • McKesson Supplier of the Year Award - 2019 • Walmart Supplier of the Year Award - 2018 • Cardinal Supply Chain Excellence Award – 2018 • Dr. Desh Bandhu Gupta inducted into the ‘Hall of Fame’, CNBC-TV18 – India Business Leader Awards 2018 • Vinita Gupta: Vogue and IBM
Slide 5: Q2 FY2020 Snapshot
Q2 FY2020 Snapshot Sales (INR Mn, YoY Growth) Important developments India, Commercial North America, Mr. Nilesh.D.Gupta 13,419, 12% 13,244, 6% Managing Director • India branded formulations (grew 12.8% YoY) continued Lupin Limited to outpace IPM growth • MEK Inhibitor licensed to Boehringer Ingelhe
Slide 6: Strategic Vision
Strategic Vision Well Diversified Pharma Business Strong Complex Specialty Foundation Generics Focus Focus Amongst the Top 10 Committed to building Focus on delivering generic companies in a strong specialty high barrier products the World business Sustain and Grow Portfolio Execution Build • Major
Slide 7: Q2 FY2020 Financial Results Review
Q2 FY2020 Financial Results Review
Slide 8: P&L Highlights – Q2 FY2020
P&L Highlights – Q2 FY2020 % of % of QoQ % of YoY Amount in INR mn Q2 FY20 Q1 FY20 Q2 FY19 sales sales growth sales growth Net sales 42,969 100.0% 43,558 100.0% (1.4%) 38,909 100.0% 10.4% Other operating income 628 626 601 Total revenue 43,597 44,184 (1.3%) 39,510 10.3% Gross profit 27,696 64.5% 28,
Slide 9: North America
Q2FY20 North America 31% 35% YoY 6.1% QoQ 14.1% Stabilized base business Lupin consolidating its position in US1 US quarterly sales ($ mn) 245 218 31.7% average 194 184 market share1 171 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 US portfolio progressing • Expect Levothyroxine to ramp up, with approval
Slide 10: India
Q2FY20 India 31% 35% YoY 11.5% QoQ 2.6% India business continues to be robust Consistently outpacing industry growth India quarterly Sales (INR bn) 3 Year CAGR% Lupin Rank1 13.1 13.4 MAT MAT 12.0 11.9 Therapy Market Lupin 10.5 Sep-16 Sep-19 Acute 8% 7% 12 13 Chronic 11% 15% 6 4 Cardiac 9% 10% 2 3 Q2
Slide 11: APAC
Q2FY20 APAC 15% 35% YoY 2.4% QoQ 5.4% APAC sales evolution (INR bn) 1.2 1.4 1.1 1.1 1.3 Performance highlights 5.7 5.5 5.6 Japan 5.1 5.1 • On track to launch bEtanercept in H2FY20 • Bipresso® Q2 sales up 130% QoQ/325% YoY; Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 ongoing co-promotion with Yoshitomi J
Slide 12: Other Markets
Other Markets • Germany: EUR 9.6 mn sales in Q2 FY20 (up 32% YoY) Developed • ARV’s, Women´s Health and CNS are the key focus therapeutic segments EU5 • NaMusclaTM - Launched with Orphan drug designation in UK, Germany and France; Partnering discussions in advanced stages for other EU markets • 3rd
Slide 13: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence OPERATIONS 100 25 9 Countries where Countries with Countries with RESEARCH products are sold marketing offices subsidiaries 18 9 Manufacturing Sites R&D Sites ◼ 12 USFDA inspected sites ◼ 427 US ANDAs; 274 approved ◼ 30 bn+ ex
Slide 14: R&D – Higher focus on complex products and FTFs
R&D – Higher focus on complex products and FTFs Invested INR 4.4 bn or 10.1% of sales on R&D in Q2FY20 at 9 R&D sites globally Optimizing R&D spend US Pipeline 5.0 9.7% 9.7% 10.1% 9.2% 8.7% 10.0% 427 cumulative filings 4.0 8.0% 3.0 6.0% 2.0 4.3 4.0 4.4 3.8 3.8 4.0% 153 pending approval 1.0 2.0% 0.0
Slide 15: Thank You
L LUPIN THANK YOU